Spots Global Cancer Trial Database for refractory cll
Every month we try and update this database with for refractory cll cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01082939 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Alemtuzumab Rituximab | - | M.D. Anderson Cancer Center | |
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). | NCT02980731 | Chronic Lymphoc... | Venetoclax | 18 Years - 99 Years | AbbVie | |
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL | NCT00772486 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL | NCT00772486 | Chronic Lymphoc... | ISF35 | 18 Years - | Memgen, Inc. | |
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01082939 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Alemtuzumab Rituximab | - | M.D. Anderson Cancer Center |